Bolt Biotherapeutics Inc. (BOLT)
0.38
-0.02 (-5.00%)
At close: Apr 01, 2025, 3:58 PM
0.39
1.91%
After-hours: Apr 01, 2025, 05:11 PM EDT
-5.00% (1D)
| Bid | 0.34 |
| Market Cap | 14.68M |
| Revenue (ttm) | 7.7M |
| Net Income (ttm) | -63.21M |
| EPS (ttm) | -1.65 |
| PE Ratio (ttm) | -0.23 |
| Forward PE | -0.56 |
| Analyst | Hold |
| Ask | 0.5 |
| Volume | 167,251 |
| Avg. Volume (20D) | 131,831 |
| Open | 0.41 |
| Previous Close | 0.40 |
| Day's Range | 0.38 - 0.42 |
| 52-Week Range | 0.38 - 1.48 |
| Beta | 0.94 |
About BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for col...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 52
Stock Exchange NASDAQ
Ticker Symbol BOLT
Website https://www.boltbio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for BOLT stock is "Hold." The 12-month stock price forecast is $1.12, which is an increase of 192.43% from the latest price.
Stock ForecastsEarnings Surprise
Bolt Biotherapeutics has released their quartely earnings
on Mar 24, 2025:
Next Earnings Release
Bolt Biotherapeutics Inc. is scheduled to release its earnings on May 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
10 months ago
-37.12%
Bolt Biotherapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
10 months ago
-0.75%
Bolt Biotherapeutics shares are trading lower. The company reported Q1 financial results.
